Pink Luminous Breast Takes Steps Toward FDA Class III Approval
New Clinical Study Validates PLB as a Quality Breast Screening Tool
News provided by
Share this article
Share this article
MIAMI, May 7, 2021 /PRNewswire/ Pink Luminous Breast (PLB) is continuing to make strides in breast cancer awareness with a new clinical study released exploring the potential recommendation of the device to be used for routine breast screenings in non-clinical settings. The PLB device is not intended to replace the annual mammogram but does provide a form of screening in-between exams, and for women under the age of 40, who do not qualify for a mammogram yet based on the estimated risk score. Because breast cancer is the leading cause of female specific cancer death in the United States, detection at earlier stages contributes to decreasing the mortality rate. The study validates the use of the PLB device as a complement tool, providing more efficient earlier detection strategies. Funding for